Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 16 new non-executive employees. The awards include 32,135 non-qualified stock options at an exercise price of $9.65 per share and 64,320 restricted stock units (RSUs).
The stock options have a 10-year term with a 4-year vesting schedule, starting with 25% vesting after one year and the remainder monthly over three years. The RSUs will vest in approximately equal annual installments over four years beginning August 15, 2026. These awards were granted under the company's 2025 Inducement Plan and approved under Nasdaq Listing Rule 5635(c)(4).
Replimune (NASDAQ: REPL), una societ脿 biotecnologica in fase clinica specializzata in immunoterapie oncolitiche, ha concesso premi azionari di incentivo a 16 nuovi dipendenti non esecutivi. I premi comprendono 32.135 opzioni azionarie non qualificate con un prezzo di esercizio di 9,65 dollari per azione e 64.320 unit脿 di azioni vincolate (RSU).
Le opzioni azionarie hanno una durata di 10 anni con un piano di maturazione di 4 anni, che prevede il maturare del 25% dopo un anno e il resto mensilmente nei successivi tre anni. Le RSU matureranno in rate annuali approssimativamente uguali per quattro anni a partire dal 15 agosto 2026. Questi premi sono stati concessi nell'ambito del Piano di Incentivazione 2025 della societ脿 e approvati in conformit脿 alla Regola 5635(c)(4) del Nasdaq.
Replimune (NASDAQ: REPL), una empresa biotecnol贸gica en etapa cl铆nica centrada en inmunoterapias oncol铆ticas, ha otorgado premios de acciones de incentivo a 16 nuevos empleados no ejecutivos. Los premios incluyen 32,135 opciones sobre acciones no calificadas con un precio de ejercicio de $9.65 por acci贸n y 64,320 unidades restringidas de acciones (RSU).
Las opciones tienen un plazo de 10 a帽os con un calendario de adquisici贸n de derechos de 4 a帽os, comenzando con un 25% adquirido despu茅s de un a帽o y el resto mensualmente durante los siguientes tres a帽os. Las RSU se adquirir谩n en cuotas anuales aproximadamente iguales durante cuatro a帽os a partir del 15 de agosto de 2026. Estos premios se otorgaron bajo el Plan de Incentivos 2025 de la compa帽铆a y fueron aprobados conforme a la Regla 5635(c)(4) de Nasdaq.
Replimune (NASDAQ: REPL)鞚� 膦呾枒鞖� 氅挫棴旃橂鞝滌棎 歆戩頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 16氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 鞙犾澑 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 氤挫儊鞐愲姅 欤茧嫻 頄夓偓 臧�瓴╈澊 $9.65鞚� 32,135臧滌潣 牍勳瀽瓴� 欤检嫕鞓奠厴瓿� 64,320臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
欤检嫕鞓奠厴鞚赌 10雲� 毵岅赴鞚措┌, 4雲� 氩犾姢韺� 鞚检爼鞐� 霐半澕 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆�電� 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. RSU電� 2026雲� 8鞗� 15鞚�攵�韯� 鞁滌瀾頃橃棳 4雲勳棎 瓯胳硱 瓯办潣 霃欖澕頃� 鞐瓣皠 頃犽秬搿� 氩犾姢韺呺惄雼堧嫟. 鞚� 氤挫儊鞚� 須岇偓鞚� 2025雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 鞚橅暣 鞀轨澑霅橃棃鞀惦媹雼�.
Replimune (NASDAQ : REPL), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les immunoth茅rapies oncolytiques, a attribu茅 des actions incitatives 脿 16 nouveaux employ茅s non cadres. Ces r茅compenses comprennent 32 135 options d'achat d'actions non qualifi茅es au prix d'exercice de 9,65 $ par action et 64 320 unit茅s d'actions restreintes (RSU).
Les options d'achat ont une dur茅e de 10 ans avec un calendrier d'acquisition sur 4 ans, d茅butant par 25 % acquis apr猫s un an, puis le reste mensuellement sur les trois ann茅es suivantes. Les RSU seront acquises en versements annuels approximativement 茅gaux sur quatre ans 脿 partir du 15 ao没t 2026. Ces r茅compenses ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation 2025 de la soci茅t茅 et approuv茅es conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq.
Replimune (NASDAQ: REPL), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Schwerpunkt auf onkolytischen Immuntherapien, hat Anreizaktien an 16 neue nicht-exekutive Mitarbeiter vergeben. Die Auszeichnungen umfassen 32.135 nicht qualifizierte Aktienoptionen mit einem Aus眉bungspreis von 9,65 USD pro Aktie sowie 64.320 Restricted Stock Units (RSUs).
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierj盲hrigen Vesting-Zeitplan, beginnend mit 25 % Vesting nach einem Jahr und dem Rest monatlich 眉ber die folgenden drei Jahre. Die RSUs werden in etwa gleichm盲脽igen j盲hrlichen Raten 眉ber vier Jahre ab dem 15. August 2026 vesten. Diese Auszeichnungen wurden im Rahmen des Inducement-Plans 2025 des Unternehmens gew盲hrt und gem盲脽 der Nasdaq-Listenregel 5635(c)(4) genehmigt.
- Successful recruitment of 16 new employees indicating company growth
- Structured equity compensation plan to retain talent
- Potential dilution from new equity awards totaling 96,455 shares
WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 16 employees as a material inducement to commencing their employment with the Company under the Company鈥檚 2025 Inducement Grant Incentive Compensation Plan (the 鈥淚nducement Plan鈥�). The inducement awards consist of non-qualified stock options to purchase an aggregate of 32,135 shares of the Company's common stock and restricted stock units representing an aggregate of 64,320 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). The inducement awards are subject to the terms and conditions set forth under the Inducement Plan.
础产辞耻迟听搁别辫濒颈尘耻苍别听
Replimune Group, Inc., headquartered in听Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune鈥檚 proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit听.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
FAQ
How many shares were granted in Replimune's (REPL) July 2025 inducement awards?
What is the exercise price for REPL's July 2025 inducement stock options?
What is the vesting schedule for Replimune's 2025 inducement RSUs?
How long is the vesting period for REPL's July 2025 inducement stock options?
How many new employees received Replimune's July 2025 inducement awards?
